PRMT5 activates lipid metabolic reprogramming via MYC contributing to the growth and survival of mantle cell lymphoma
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.216877 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Jin-Hua Liang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laborato…. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Protein-Arginine N-Methyltransferases, Proto-Oncogene Proteins c-myc, Lipid Metabolism. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Jiangsu Provincial Department of Science and Technology, National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Mantle cell lymphoma (MCL) is an incurable and aggressive subtype of non-Hodgkin B-cell lymphoma. Increased lipid uptake, storage, and lipogenesis occur in a variety of cancers and contribute to rapid tumor growth. However, no data has been explored for the roles of lipid metabolism reprogramming in MCL. Here, we identified aberrant lipid metabolism reprogramming and PRMT5 as a key regulator of cholesterol and fatty acid metabolism reprogramming in MCL patients. High PRMT5 expression predicts adverse outcome prognosis in 105 patients with MCL and GEO database (GSE93291). PRMT5 deficiency resulted in proliferation defects and cell death by CRISPR/Cas9 editing. Moreover, PRMT5 inhibitors including SH3765 and EPZ015666 worked through blocking SREBP1/2 and FASN expression in MCL. Furthermore, PRMT5 was significantly associated with MYC expression in 105 MCL samples and the GEO database (GSE93291). CRISPR MYC knockout indicated PRMT5 can promote MCL outgrowth by inducing SREBP1/2 and FASN expression through the MYC pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, China;…
- Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Förderung
- Jiangsu Provincial Department of Science and Technology
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Zitieren
APA
Liang, J. H., Wang, W. T., Wang, R., Gao, R., Du, K. X., Duan, Z. W., Zhang, X. Y., Li, Y., Wu, J. Z., Yin, H., Shen, H. R., Wang, L., Li, J. Y., Guo, J. R., & Xu, W. (2024). PRMT5 activates lipid metabolic reprogramming via MYC contributing to the growth and survival of mantle cell lymphoma. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216877
Vancouver
Liang JH, Wang WT, Wang R, Gao R, Du KX, Duan ZW, et al. PRMT5 activates lipid metabolic reprogramming via MYC contributing to the growth and survival of mantle cell lymphoma. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216877
BibTeX
@article{Liang2024,
author = {Liang, Jin-Hua and Wang, Wei-Ting and Wang, Rong and Gao, Rui and Du, Kai-Xin and Duan, Zi-Wen and Zhang, Xin-Yu and Li, Yue and Wu, Jia-Zhu and Yin, Hua and Shen, Hao-Rui and Wang, Li and Li, Jian-Yong and Guo, Jin-Ran and Xu, Wei},
title = {PRMT5 activates lipid metabolic reprogramming via MYC contributing to the growth and survival of mantle cell lymphoma},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.216877}
}
EUVIMED